|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:protease_inhibitor
gptkb:chemical_compound
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:alsoKnownAs
|
gptkb:AZT
gptkb:zidovudine
|
|
gptkbp:approvedForUse
|
1987
|
|
gptkbp:ATCCode
|
J05AF01
|
|
gptkbp:brand
|
gptkb:Retrovir
|
|
gptkbp:CASNumber
|
30516-87-1
|
|
gptkbp:category
|
gptkb:antiretroviral_therapy
gptkb:antiviral_drug
gptkb:HIV_drug
gptkb:WHO_essential_medicine
thymidine analogue
|
|
gptkbp:contraindication
|
severe anemia
hypersensitivity
|
|
gptkbp:developedBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discoveredBy
|
gptkb:Jerome_Horwitz
|
|
gptkbp:discoveredIn
|
1964
|
|
gptkbp:eliminationHalfLife
|
1 hour
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstAntiretroviralApproved
|
true
|
|
gptkbp:hasMolecularFormula
|
C10H13N5O4
|
|
gptkbp:includedIn
|
combination antiretroviral therapy
|
|
gptkbp:KEGGID
|
D00322
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:MeSH_ID
|
D015215
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
267.241 g/mol
|
|
gptkbp:patentExpired
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL458
35370
DB00495
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
gptkb:muscular_dystrophy
nausea
headache
neutropenia
|
|
gptkbp:UNII
|
X4X229T896
|
|
gptkbp:usedFor
|
HIV/AIDS treatment
|
|
gptkbp:bfsParent
|
gptkb:AZT_(zidovudine)
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
azidothymidine
|